Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cance...
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
About this item
Full title
Author / Creator
on behalf of the Multicentre Italian Trials in Ovarian cancer (MITO-7) , Mario Negri Gynecologic Oncology (MaNGO) , European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10) , Gynecologic Cancer InterGroup (GCIG) Investigators , Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO) , Multicentre Italian Trials in Ovarian cancer (MITO-7) , Pignata, Sandro, Dr , Scambia, Giovanni, Prof , Katsaros, Dionyssios, Prof , Gallo, Ciro, Prof , Pujade-Lauraine, Eric, Prof , De Placido, Sabino, Prof , Bologna, Alessandra, MD , Weber, Beatrice, MD , Raspagliesi, Francesco, MD , Panici, Pierluigi Benedetti, Prof , Cormio, Gennaro, MD , Sorio, Roberto, MD , Cavazzini, Maria Giovanna, MD , Ferrandina, Gabriella, MD , Breda, Enrico, MD , Murgia, Viviana, MD , Sacco, Cosimo, MD , Cinieri, Saverio, MD , Salutari, Vanda, MD , Ricci, Caterina, MD , Pisano, Carmela, MD , Greggi, Stefano, MD , Lauria, Rossella, MD , Lorusso, Domenica, MD , Marchetti, Claudia, MD , Selvaggi, Luigi, Prof , Signoriello, Simona, PhD , Piccirillo, Maria Carmela, MD , Di Maio, Massimo, MD and Perrone, Francesco, MD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Carboplatin plus paclitaxel administered every 3 weeks is standard first-line chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule combined with carboplatin every 3 weeks prolonged progression-free survival and overall survival in a Japanese phase 3 trial. The aim of our study was to assess whether...
Alternative Titles
Full title
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Authors, Artists and Contributors
Author / Creator
Mario Negri Gynecologic Oncology (MaNGO)
European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10)
Gynecologic Cancer InterGroup (GCIG) Investigators
Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO)
Multicentre Italian Trials in Ovarian cancer (MITO-7)
Pignata, Sandro, Dr
Scambia, Giovanni, Prof
Katsaros, Dionyssios, Prof
Gallo, Ciro, Prof
Pujade-Lauraine, Eric, Prof
De Placido, Sabino, Prof
Bologna, Alessandra, MD
Weber, Beatrice, MD
Raspagliesi, Francesco, MD
Panici, Pierluigi Benedetti, Prof
Cormio, Gennaro, MD
Sorio, Roberto, MD
Cavazzini, Maria Giovanna, MD
Ferrandina, Gabriella, MD
Breda, Enrico, MD
Murgia, Viviana, MD
Sacco, Cosimo, MD
Cinieri, Saverio, MD
Salutari, Vanda, MD
Ricci, Caterina, MD
Pisano, Carmela, MD
Greggi, Stefano, MD
Lauria, Rossella, MD
Lorusso, Domenica, MD
Marchetti, Claudia, MD
Selvaggi, Luigi, Prof
Signoriello, Simona, PhD
Piccirillo, Maria Carmela, MD
Di Maio, Massimo, MD
Perrone, Francesco, MD
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1751213175
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751213175
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(14)70049-X
